Solve ME said:This year, Solve M.E. & #MEAction are partnering on a medical education initiative. As we began planning Advocacy Week this year, we took a step back and asked:
Where can our collective effort make the most meaningful difference right now?
The ME/CFS community has been pushing for better and more widespread knowledge among medical providers for decades. The introduction of ME/CFS knowledge into medical education and national medical exams has been a long-time focus for ME/CFS advocacy groups. Over the past few months, Solve M.E. & #MEAction have been partnering in strategic work to initiate conversations with partner organizations, clinicians, and advocates across the ME/CFS, Long COVID, and infection-associated chronic conditions (IACC) community, asking a central question:
How can we close the knowledge gap in ME/CFS and Long COVID care?
The Ask: We will meet with state and local healthcare leaders and ask for their support for introducing questions on ME/CFS and Long COVID medical exams at the national level.
The Theory of Change: By reaching out to patient safety/regulatory agencies, State Medical Boards, and State Health Leadership/Chief Medical Officers by state, framing ME/CFS education gaps as a patient safety and standard-of-care issue, we will move IACC’s such as ME/CFS and Long COVID from “optional knowledge” to “standardized knowledge” in clinical care.
Target: State healthcare leadership and patient safety agencies
" Bateman Horne Center's strong work in medical education and regulatory initiatives with Open Medicine Foundation’s Medical Education Resource Center (MERC), and #MEAction, engaged in conversation with patients and state licensing boards, contributing to clinician education standards."
Another update from Solve ME. They're asking US residents to contact their government representatives:
It includes an automated tool to help folks contact Congress.
ME Action, and also Not Just Fatigue, joined in writing formal letters to progress these three requests.
It makes a big difference if more Members of Congress sign these letters, asking for:
$10,000,000 now, to top up the $5,400,000 CFS Program at CDC Centre for Disease Control:
- top-up requested as the Program was stuck for 30 years, and Covid still makes more ME / CFS.
The Department of Defence to secure the place it keeps for ME / CFS in its peer-reviewed medical research program:
- protection requested as the Defence Department is a vital source of funds for ME / CFS research
$50,000,000 to implement the NIH ME / CFS Research Roadmap, already recognised by Congress:
- progress requested to action this plan for biomarker(s), the tools of diagnosis, and clinical trials
Throughout the week, participants will receive clear daily action steps, templates, and guidance. You may participate at your own pace
Solve ME said:“standardized knowledge in clinical care - lack of training is creating a medical gap in which patients are experiencing more debility and prolonged care interventions, which then leads to poor patient outcomes, increased disability cases, and higher unemployment rates."
ME Action joined in the Solve ME Advocacy Week (2026) to launch regional letters, aiming to:
- frame the missing quality control and patient-safety, as it requires consistent clinical training
- standardise clinical knowledge, as it is still inconsistent, unsafe, and substandard
- convince regional leaders, regulators, patient safe-guarders, and medical boards to:
* co-operate
* fill confusing gaps in training, to meet quality control in clinical service, and to safeguard patients
* add standard ME / CFS knowledge to licensing procedure and exams
- also spread the three requests to fund more research (see above)
I can't find the research funding letters.
Solve ME said:Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion, reducing appetite, and increasing insulin release.
But can they also ease symptoms in people with ME/CFS and identify disease subtypes?
Solve Ramsay Research Grant Program alum Dr. Carmen Scheibenbogen (acting director of the Institute for Medical Immunology of the Charité University Hospital in Berlin) recently received a Solve ME/CFS Catalyst Award for her study evaluating whether semaglutide reduces symptoms and improves quality of life for people with ME/CFS who have high BMI.
In this free educational webinar hosted by Solve VP of Scientific Programs Dr. Jessica Maya, Dr. Scheibenbogen will discuss details of her study, explain how her research will identify biomarkers, and discuss how these results could help determine which patients are most likely to benefit from treatment.